CD123 targeting represents an effective therapeutic option for BPDCN patients and tagraxofusp, a drug based on a genetically engineered diphtheria toxin fused with IL-3, has shown robust activity and BPDCN was the first IL-3Rα targeting agent approved for the treatment of a hematological malignancy. The gene discussed is IL3RA; the disease is hematologic disorder.